Roche Points To Pipeline Depth Beyond Oncology
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
At a late-stage pipeline review, Roche execs stressed the advances being made outside the company’s specialty focus on oncology, including neuroscience, inflammation and ophthalmology.